SFEE: Clawback & Rebate is the definition of mismanagement and failure

The Board of SFEE, expressed frustration about the taxes of the horizontal policy. For the mechanism of the clawback, Mr. Frouzis argued that on the part of the government means: "Whatever you do, I will get my money back." The clawback is bad policy definition, noted the president of SFEE. Along with the Rebate is a failure, when you have the lowest price in Europe in originals drugs.

As stated by the SFEE's deputy chairman Mr. Paschalis Apostolidis, "Given the wrong budget of 2 billion. Euros (for pharmaceutical expenditure), companies in the industry will incur of clawback of over 400 million Euros, representing an increase of 30% (in the last two years) in the percentage return, which the pharmaceutical industry is forced to pay for an incomplete budget.

And while thus is proving again the inability of the government to cover the insured within the existing budget, the new decree wants 340 million Euros of this budget to be directed to the care of the uninsured without first having attempted to rationalize other costs that may release significant resources."

The Board SFEE proposed that the maximum limit of the excess return of the pharmaceutical expenditure (clawback) should not exceed 150 million Euros for 2014 and should not exceed 2% of the annual target from 2015 onwards, if there is a certified exceedance and have implement the necessary structural reforms.
Finally, says no to "unfairly additional rebates, the amount of which exceeds 400 million Euros and the pharmaceutical industry cannot support."

It is worth noting that the Clawback and the Rebate that all the pharmaceutical companies must pay for 2014, was 585 million Euros in a pharmaceutical spending 2 billion Euros, while in 2013 was 362 million in spending of 2.371 billion Euros, and in 2012 was 198 million in spending of 2.88 billion Euros. That means that the participation of the pharmaceutical industry in drug spending from 6.9% in 2012, currently amounts to 30% and last year to 15.3%.

Source: onmed.gr